BUDGET IMPACT OF SELINEXOR COMBINATION REGIMENS IN PREVIOUSLY TREATED MULTIPLE MYELOMA

被引：0
|
作者：
Carter, J. A. [1 ]
Ijioma, S. [2 ]
Ray, D. [3 ]
机构：
[1] OPEN Hlth, Bethesda, MD USA
[2] Karyopharm Therapeut Inc, Marietta, GA USA
[3] Karyopharm Therapeut Inc, Newton, MA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE403
引用
收藏
页码：S131 / S131
页数：1
相关论文
共 50 条
  • [31] Selinexor's Immunomodulatory Impact in Advancing Multiple Myeloma Treatment
    Tasbihi, Kereshmeh
    Bruns, Heiko
    CELLS, 2025, 14 (06)
  • [32] Selinexor and dexamethasone in multiple myeloma
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (03): : E146 - E146
  • [33] Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor
    Mikhael, Joseph
    Noonan, Kimberly R.
    Faiman, Beth
    Gleason, Charise
    Nooka, Ajay K.
    Costa, Luciano J.
    Jagannath, Sundar
    Richardson, Paul G.
    Siegel, David
    Chari, Ajai
    Lentzch, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (06): : 351 - 357
  • [34] Determining optimal combination regimens for patients with multiple myeloma
    Aghaee, Mahya
    Ledzewicz, Urszula
    Robbins, Michael
    Bezman, Natalie
    Cho, Hearn Jay
    Moore, Helen
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 187
  • [35] BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN RUSSIA
    Pyadushkina, E.
    Derkach, E., V
    Boyarskaya, T.
    VALUE IN HEALTH, 2018, 21 : S26 - S26
  • [36] BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN BRAZIL
    Sakagute, M.
    Tanaka, P. Y.
    Duva, A.
    Rigolon, J.
    VALUE IN HEALTH, 2019, 22 : S459 - S459
  • [37] Selinexor treatment of multiple refractory multiple myeloma
    Stocker, Nicolas
    HEMATOLOGIE, 2019, 25 (06): : 282 - 283
  • [38] Use of Daratumumab in Patients With Previously Treated Multiple Myeloma
    Patel, Ashwin P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14)
  • [39] Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma
    Huang, Shang-Xiao
    Luo, Peng-Hui
    Wang, Han-Lei
    Mo, Dun-Chang
    Huang, Jian-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2667 - 2668
  • [40] Selinexor, Bortezomib, and Dexamethasone (SVD) in Heavily Treated Relapsed Refractory Multiple Myeloma
    Mouhieddine, Tarek
    Parekh, Samir
    Cho, Hearn Jay
    Richter, Joshua
    DeCastro, Andrew
    Shah, Jatin
    Landesman, Yosef
    Chari, Ajai
    Jagannath, Sundar
    Madduri, Deepu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S292 - S293
12345